Clarithromycin, a new and well tolerated, acid stable macrolide antibiotic, has a similar antimicrobial spectrum to erythromycin but a better in vitro MIC90 (0.03 itg/l-1) against Helicobacter pylon (H pylori). This study aimed at determining the eradication rate using clarithromycin 500 mg thrice daily and omeprazole 40 
(13C-UBT, European standard protocol, positive result=excess b13CO2 excretion >5 per mil). Compliance waa assessed by returned tablet counts. H pylori clearance at the end of treatment and eradication four weeks after finishing treatment were assessed by the '3C-UBT. Seventy 40 mg in the morning and amoxycillin 750 mg twice daily found an overall eradication rate of 54% although in compliant patients (<33% of study population) the eradication rate was 74%. 24 The eradication rate of the omeprazole and clarithromycin dual therapy recorded in this study compares favourably with that of standard triple therapy. Although the eradication rate was lower in patients previously treated for H pylori, this did not seem to be because of differences in patient compliance or antimicrobial sensitivity and was not seen in previous studies.3 13 21 At the comparatively high doses, similar to those used in this study, clarithromycin may cause a metallic taste (manufacturer's data). Patients 
